Blood stream infection is a condition in which the blood is detected with bacterial, fungal, or any other infection. This condition normally occurs when the infection enters the blood stream of any part of body through wound, injection or during any surgical procedures. This infection is also considered as blood poisoning, bacteremia, septicemia, or sepsis. Self-diagnosis of blood stream infections is difficult, owing to its common symptoms (such as chills, fever, diarrhea, vomiting, and others), thereby testing is mandatory for detection of infections in blood.
Market Dynamics
Increasing prevalence of infections such as abdominal infections, dental infections, kidney and urinary infection, and chronic diseases drives the market growth. According to the World Health Organization (WHO), in 2016, over 30 million people are affected by sepsis worldwide, annually, leading to 6 million deaths. Moreover, increasing R&D investments related to bloodstream infection testing is also expected to boost the market growth. Moreover, high incidences of burns/wounds cases, HIV, pneumonia, pyelonephritis, and cancer along with growing awareness about hygiene is also expected to boost the global bloodstream infection testing market growth. According to World Health Organization, at the end of 2017, approximately 36.9 million people living with HIV and 1.8 million people becoming newly ininfected in 2017 globally. However, the high diagnostic costs and insufficiency medical reimbursement may hinder the market growth.
Key features of the study:
- This report provides in-depth analysis of the bloodstream infection testing market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2019 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bloodstream infection testing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans.
- Key companies covered as a part of this study include, BioMérieux SA, Becton, Dickinson and Company, AB Sciex, IRIDICA, Abbot Laboratories, Cepheid Inc., C. R. Bard, Inc., F. Hoffmann-La Roche AG, Nanoshpere, Dade Behring, AdvanDX, Siemens Healthcare.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global bloodstream infection testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the bloodstream infection testing market
Detailed Segmentation:
- Global Bloodstream Infection Testing Market, By Product Type:
- Instruments
- Reagents
- Others
- Global Bloodstream Infection Testing Market, By Technology:
- Conventional Testing
- Non-conventional Testing
- Global Bloodstream Infection Testing Market, By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- Global Bloodstream Infection Testing Market, By End User:
- Hospitals
- Independent Diagnostics Centers
- Others
- Global Bloodstream Infection Testing Market, By Region:
- North America
- By Product Type:
- Instruments
- Reagents
- Others
- By Technology:
- Conventional Testing
- Non-conventional Testing
- By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- By End User:
- Hospitals
- Independent Diagnostic Centers
- Others
- By Country:
- Latin America
- By Product Type:
- Instruments
- Reagents
- Others
- By Technology:
- Conventional Testing
- Non-conventional Testing
- By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- By End User:
- Hospitals
- Independent Diagnostic Centers
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- Instruments
- Reagents
- Others
- By Technology:
- Conventional Testing
- Non-conventional Testing
- By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- By End User:
- Hospitals
- Independent Diagnostic Centers
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Instruments
- Reagents
- Others
- By Technology:
- Conventional Testing
- Non-conventional Testing
- By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- By End User:
- Hospitals
- Independent Diagnostic Centers
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type:
- Instruments
- Reagents
- Others
- By Technology:
- Conventional Testing
- Non-conventional Testing
- By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- By End User:
- Hospitals
- Independent Diagnostic Centers
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Instruments
- Reagents
- Others
- By Technology:
- Conventional Testing
- Non-conventional Testing
- By Test Type:
- Conventional Blood Culture Tests
- PCR Method
- Nucleic Acid Testing
- Mass Spectroscopy
- Point-of-Care Testing
- By End User:
- Hospitals
- Independent Diagnostic Centers
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- BioMérieux SA*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Becton, Dickinson and Company
- AB Sciex
- IRIDICA
- Abbot Laboratories
- Cepheid Inc.
- C. R. Bard, Inc.
- F. Hoffmann-La Roche AG
- Nanoshpere
- Dade Behring
- AdvanDX
- Siemens Healthcare
“*” marked represents similar segmentation in other categories in the respective section.
